Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

Journal of Nanobiotechnology

Lei Song¹  Hongmei Liu¹  You Xu² 

[1] Department of Respiratory Medicine, Key Laboratory of Organ Regeneration & Transplantation of the Ministry of Education, The First Hospital of Jilin University, 130061, Changchun, People’s Republic of China;Department of Respiratory Medicine, Key Laboratory of Organ Regeneration & Transplantation of the Ministry of Education, The First Hospital of Jilin University, 130061, Changchun, People’s Republic of China;Department of Pharmacy, Faculty of Health & Medical Sciences, University of Copenhagen, 2100, Copenhagen, Denmark;

关键词: Oxidative stress;    Chronic obstructive pulmonary disease;    Drug delivery;    Nanoparticles;    Microparticles;    Nanocomposite microparticles;   

DOI  :  10.1186/s12951-020-00703-5

来源: Springer

【 摘 要 】

Oxidative stress is significantly involved in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). Combining antioxidant drugs or nutrients results in a noteworthy therapeutic value in animal models of COPD. However, the benefits have not been reproduced in clinical applications, this may be attributed to the limited absorption, concentration, and half-life of exogenous antioxidants. Therefore, novel drug delivery systems to combat oxidative stress in COPD are needed. This review presents a brief insight into the current knowledge on the role of oxidative stress and highlights the recent trends in novel drug delivery carriers that could aid in combating oxidative stress in COPD. The introduction of nanotechnology has enabled researchers to overcome several problems and improve the pharmacokinetics and bioavailability of drugs. Large porous microparticles, and porous nanoparticle-encapsulated microparticles are the most promising carriers for achieving effective pulmonary deposition of inhaled medication and obtaining controlled drug release. However, translating drug delivery systems for administration in pulmonary clinical settings is still in its initial phases.

【 授权许可】

CC BY